Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies.
about
Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersSustained proliferation in cancer: Mechanisms and novel therapeutic targetsEpithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation.Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesIBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways.ErbB/EGF signaling and EMT in mammary development and breast cancer.New promising drug targets in cancer- and metastasis-initiating cells.Cyclin D1, Id1 and EMT in breast cancer.Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrenceFunctional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition.Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.Relevance of periostin splice variants in renal cell carcinomaFrequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer.TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinomaRecent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.Epithelial-mesenchymal transition in cervical carcinoma.Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.Development of animal models underlining mechanistic connections between prostate inflammation and cancerFunctions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.Urothelium-derived Sonic hedgehog promotes mesenchymal proliferation and induces bladder smooth muscle differentiationRecent progress on tissue-resident adult stem cell biology and their therapeutic implications.Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination.Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications.Role of Annexin A2 in the EGF-induced epithelial-mesenchymal transition in human CaSki cells.Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancerSmooth muscle differentiation and patterning in the urinary bladder.Bioengineering approaches to study multidrug resistance in tumor cells.Immunotherapy targeting glioma stem cells--insights and perspectives.Role of cancer stem cells in spine tumors: review of current literature.Differential remodeling of cadherins and intermediate cytoskeletal filaments influence microenvironment of solid and ascitic sarcoma.KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.BAG3 regulates epithelial-mesenchymal transition and angiogenesis in human hepatocellular carcinoma.Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition.Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
P2860
Q26822406-675846C7-7BDC-4143-BE78-43C3037E9A5FQ28396388-389E5EFC-62E9-4719-B6C9-6885151AF4EAQ33375703-97533842-5D56-4621-AD22-D3B15D9F6DFBQ33719099-95CC38AA-910A-4194-A266-2C732949014CQ33730375-09B41A9A-BE0A-4741-8FEE-6F5C5358824AQ33833425-A798BBC1-8D87-4AA6-8699-53A25EE6540EQ33927493-C134EC3C-B534-4F3E-969B-0F5E5D067A07Q34003691-B430D821-760A-4E4B-B7C1-4E58AA32A506Q34034112-0028371D-D2D1-4EEC-8AC0-F4A986E9166FQ34244929-428C4457-B865-4837-8454-9FC1E2980D6CQ34382586-EEBBC5E7-00BF-495D-B4EB-5A5E7044217AQ34382914-6653D474-8146-491C-8A47-6A82E2ECAA7AQ34449946-249D50C5-EA84-4780-A5A4-39CB0904CC66Q35161856-8FFC70A3-5E89-4738-8A31-112673595098Q35167831-9DA64C57-7F8A-40A8-BD6C-11924247BA3DQ35287094-2004215E-26FC-4E46-8796-21DCFD43BDAEQ35416836-23F937FB-1A11-4BC9-8BFE-8F7872E14CC1Q35439332-6E191EFA-5DCD-4C12-877E-ABDB726D1008Q35459525-1C195465-B65F-49D4-8D7B-89AFB62FBF6AQ35747467-510F7A61-6414-4887-A2F4-1AF6B3A617EAQ35768450-5AC1A57E-949B-4814-9B4D-EE616C2BF1EDQ36718905-41938385-2DA4-4C0D-871F-0078AC267484Q36860976-4A1D992F-A201-4EE6-8A56-9AD811EE00C6Q37017497-D9CF0805-1976-4FEC-9127-D3E68DBA5653Q37089825-8B1E2D09-B880-4AFA-A8CE-A3A2979910E7Q37113566-32DBE0FF-5C51-4009-A4B0-EB9DACC49F56Q37144023-7FC03F5E-005B-4449-A9FF-1412E2C34C56Q37310063-B910E04E-038A-413F-93B0-6AFC5C13A5B9Q37594006-BA000F78-025D-4932-AECA-D19BA7D07C72Q37610799-69F3CEB1-4F28-492B-A839-5B9E05EB68E0Q37673528-CFC386E9-B9BE-43F9-A4E5-287534B3D715Q37764509-8F7240AA-FEC9-40C8-8DB8-196DD0A08CB6Q37851027-1FA43CC0-E279-46EE-9657-BC18317C31CFQ37971408-FDCBE663-4310-439B-ADE8-315245235093Q37993701-44B86ABE-3F6C-43C2-A327-A2A60D784E83Q38937115-E71EB03D-A9DC-4D96-B214-2B0B09504F34Q38984603-3C9C5839-6902-4A3F-B1AC-F9CC47799613Q39040786-308718E8-5D08-4ED7-8214-02FFC55A9E3EQ39411774-E2066E6B-FA3D-4F9F-9F4E-1BF6EAE2402DQ39998599-F505DFAB-EE0A-4ADB-9CD5-4E4D0398FCB5
P2860
Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Interplay of distinct growth f ...... ing as novel cancer therapies.
@ast
Interplay of distinct growth f ...... ing as novel cancer therapies.
@en
type
label
Interplay of distinct growth f ...... ing as novel cancer therapies.
@ast
Interplay of distinct growth f ...... ing as novel cancer therapies.
@en
prefLabel
Interplay of distinct growth f ...... ing as novel cancer therapies.
@ast
Interplay of distinct growth f ...... ing as novel cancer therapies.
@en
P356
P1433
P1476
Interplay of distinct growth f ...... ing as novel cancer therapies.
@en
P2093
P304
P356
10.1093/ANNONC/MDM070
P577
2007-03-12T00:00:00Z